Sprout Pharms Company Profile

What is the competitive landscape for SPROUT PHARMS

SPROUT PHARMS has one approved drug.

There is one US patent protecting SPROUT PHARMS drugs.

Summary for Sprout Pharms

US Patents:	1
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Sprout Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015		RX	Yes	Yes
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015		RX	Yes	Yes	7,151,103

Expired US Patents for Sprout Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	7,420,057
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	9,468,639
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	8,227,471

International Patents for Sprout Pharms Drugs

Country	Patent Number	Estimated Expiration
Hungary	0401023
China	102058597
Norway	325556

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sprout Pharms

Executive summary
Sprout Pharmaceuticals (Sprout Pharms) operates a branded-to-generic growth model built around urology and pain management portfolios. Its competitive positioning is strongest in legacy, claim-expiring products where it can leverage (i) established FDA readiness for ANDA filings, (ii) operational scale in injectable/solid oral manufacturing, and (iii) targeted litigation and settlement windows that enable calendar-driven launches. The most material threat to future revenue is not near-term competitive entry in its core categories, but the cumulative effect of patent estate attrition across multiple SKUs, creating recurring Paragraph IV and design-around pressure from other generic manufacturers. Strategic upside comes from concentrating pipeline resources on products with clear exclusivity corridors (180-day periods, pediatric/market exclusivity where applicable) and on formulation or method-of-use niches that extend usable patent life beyond mere active-ingredient coverage.

Sprout Pharms competitive landscape: market position, strengths, and strategic insights

How is Sprout Pharms positioned in the generic pharmaceutical competitive landscape?

Sprout Pharms is best understood as a niche consolidator: it competes against large-scale ANDA majors on launch timing and against smaller peers on execution quality. Its market position has historically been reinforced by a focus on a limited set of therapeutic areas where the firm can sustain reliable regulatory throughput and manufacturing consistency. Competitive outcomes in these segments typically hinge on three levers:

1. Regulatory execution: timely ANDA approval, facility readiness, and labeling alignment to avoid launch delays.
2. Patent timing control: settlement and noninfringement posture that converts discovered launch opportunities into enforceable entry dates.
3. Supply and contracting: ability to meet wholesaler and GPO demand quickly once exclusivity or settlement permits entry.

Where does Sprout Pharms compete most directly?

Competitive friction occurs primarily against:

• Large ANDA players with broad portfolio coverage and deep litigation teams
• Mid-cap generics with aggressive Paragraph IV programs in similar therapeutic niches
• Specialty/brand manufacturers where co-pay or payer dynamics drive net price outcomes even after generic entry

In high-friction categories like pain and urology, commercial wins typically require “right product, right date, right supply” because shelf placement and reimbursement depend on consistent availability.

What therapeutic areas does Sprout Pharms emphasize and how does that affect competitive risk?

Sprout Pharms’ emphasis pattern affects risk through the intersection of patent expiration density and payer sensitivity.

Patent density by therapeutic area

• Urology (often alpha-blockers, ED agents, BPH-related products) tends to have frequent lifecycle management via formulation and method-of-use patents, increasing the probability of continued patent assertions even after API protection ends.
• Pain management (opioid-adjacent and non-opioid formulations, including solids and certain controlled-release products historically in the market) carries high label-change and abuse-deterrence related complexity, raising design-around risk for generics.

Commercially, these categories can deliver durable revenue during exclusivity corridors, but also produce clustered entry waves when major brands lose protection across multiple SKUs.

How strong is Sprout Pharms’ pipeline versus larger ANDA competitors?

Sprout competes with larger peers that have higher filing volumes and more diversified exclusivity targets. Sprout’s differentiation is less “portfolio breadth” and more “targeted depth,” meaning it selects product targets where:

• the patent landscape is navigable (clear invalidity or noninfringement pathways),
• regulatory pathways are predictable,
• and manufacturing can support fast ramp.

Pipeline strength metrics that matter commercially

For competitive analysis, pipeline strength is typically evaluated via:

• approvals granted to date versus pending approvals
• expected launch dates clustered by year
• likelihood of exclusivity conversion (180-day triggers, forfeiture risk)
• probability of settlement versus sustained Paragraph IV litigation

What patents protect Sprout Pharms products, and how does patent strategy shape competition?

For Sprout-specific patent protection, the governing dataset is the FDA Orange Book for each marketed ANDA product. Sprout’s competitive posture improves when:

• it holds listed patents with enforceable claims on approved dosage form or formulation,
• its own product sits in a window where generics can enter only after patent expiry or successful litigation,
• it maintains robust patent listings that narrow design-around pathways.

How do patent estate characteristics shift generic entry risk?

Patent estates influence risk in three patterns:

1. Narrow API-only coverage: competitors design around by changing crystal form, salt, or excipient system.
2. Formulation and manufacturing method coverage: increases barriers to entry because process changes require technical and regulatory justification.
3. Method-of-use claims: narrows approval-to-label mapping because generics must avoid practicing protected use; label carve-outs become central to litigation.

What is the Orange Book status of Sprout Pharms key products?

Orange Book status (patents listed, expiration dates, exclusivity codes) is the primary determinant of entry timing. Competitive impact is greatest when:

• a Sprout-labeled product has multiple listed patents with staggered expirations,
• the product is protected by combination exclusivity (where applicable),
• and listed patents include formulation or method-of-use claims that meaningfully constrain generic labeling.

Because Orange Book listing specifics are product-by-product and jurisdictionally tied, an accurate mapping requires the product-level Orange Book dataset for each Sprout marketed NDA/ANDA.

When does Sprout Pharms lose exclusivity, and what generic entry risks follow?

Exclusivity loss risk is usually not a single event. It is a sequence:

• loss of regulatory exclusivity,
• loss of exclusivity tied to the 3-year/5-year market exclusivity (where applicable to branded products),
• and loss of patent coverage listed in the Orange Book.

The generic entry risk follows the earliest date that:

• the regulatory pathway can legally approve ANDA labeling, and
• patent infringement risk is reduced by expiration, settlement, or litigation outcomes.

For Sprout’s portfolio model, the highest risk windows are typically when multiple SKUs approach expiry in the same calendar year. Competitors can then bundle launch campaigns, raising price pressure and increasing supply competition.

How many patents cover Sprout Pharms products, and what claim types drive enforcement?

Patent count alone does not predict enforcement strength. Claim type does.

Claim types that most affect competitive outcomes

• Formulation: harder to design around without technical re-engineering and comparability work.
• Manufacturing method: can force process redesign and new analytical comparability.
• Method of use: can require label carve-outs that reduce market addressability.
• Dosing regimen: constrains “label-to-label” substitution and can protect against generic switching even after API expiry.

In competitive practice, Sprout’s strongest positions are those where claim types remain enforceable after apparent API expiry.

What Paragraph IV challenges have targeted Sprout Pharms products?

Paragraph IV challenges are the leading indicator of near-term generic threats. The risk profile depends on:

• whether the challenger is a first filer (180-day exclusivity trigger),
• whether exclusivity was forfeited (withdrawal, settlement terms, failure to market),
• whether litigation ended in a design-around settlement versus a hard launch delay.

A Sprout competitive landscape lens must map:

• the challenger identity,
• the asserted patent numbers,
• the settlement date and agreed entry date,
• and the final status of approvals and launches.

Because this turns on Orange Book-specific patent listings and court docket outcomes per product, it requires product-level litigation and FDA listing data.

What patent litigation affects Sprout Pharms, and who are the frequent challengers?

Patent litigation affects competitive timing through:

• automatic 30-month stay (where applicable),
• negotiated settlement dates,
• and injunction outcomes that delay or block launch.

Frequent challengers typically include:

• large generic brands with litigation capability,
• and repeat filers that specialize in navigating specific claim types (formulation vs method of use).

A complete mapping for Sprout’s litigation landscape requires docket-level and product-level assertion data.

What settlement agreements control Sprout Pharms generic launch dates?

Settlements control launch timing when:

• the parties agree to nonlaunch until a specified date tied to patent expiry, and/or
• the generic agrees to label limitations (carve-outs) that preserve market share.

Settlement terms also control “effective exclusivity” even when legal exclusivity might have ended, by delaying actual marketing.

Competitive insight is in settlement structure:

• “date-certain” agreements protect branded or protected branded-equivalent revenue until a defined entry date;
• “label carve-out” agreements protect clinical positioning by limiting substitution.

What regulatory pathways does Sprout Pharms rely on, and how does that compare with competitors?

Generic launches for Sprout compete across:

• ANDA for small-molecule generics and certain line extensions
• 505(b)(2) where applicable for reformulations or combination products

Competitor differentiation is commonly:

• faster review performance through successful chemistry, manufacturing, and controls (CMC) packages,
• and better management of labeling and bioequivalence strategy.

Launch speed influences net competitive position because even small delays can miss payer contract cycles.

What formulations are protected for Sprout Pharms, and how does that impact generic design-around?

Formulation protection impacts whether a competitor can “walk around” patent coverage. Common formulation design-around strategies that trigger litigation include:

• alternate salt forms or polymorph selection
• different excipient systems (stabilizers, pH modifiers)
• different release profiles (immediate versus extended)
• manufacturing-process changes that alter impurity profiles or particle size

Sprout’s enforcement strength is highest when formulation claims are broad enough to cover the competitive formulations needed for market substitutes.

How does Sprout Pharms compare with other generics in urology and pain markets?

Comparative competitive analysis usually breaks into:

• launch portfolio overlap: which competitors have ANDAs likely to launch in the same quarters
• litigation aggressiveness: number of Paragraph IV filings and settlement frequency
• supply reliability: ability to avoid shortages that trigger payer and wholesaler substitution
• pricing leverage: net price and contract terms post-entry

Sprout’s competitive advantage in this model is most often operational rather than legal. Where it wins, it tends to be because it is ready to launch when exclusivity and litigation timing align.

What generic entry risks exist for Sprout Pharms’ top-selling products?

Generic entry risks cluster around:

• imminent patent expiry windows,
• pending Paragraph IV litigation outcomes,
• and exclusivity forfeiture dynamics.

The principal risk mechanism is “early entry by others,” often a result of either:

• first filer settlement with an agreed entry date,
• or court decisions invalidating the core blocking patents.

For Sprout’s revenue, the risk is compounded when multiple competitors obtain approvals around the same period, increasing competition and reducing net prices.

Which manufacturing and IP barriers can block generic competition to Sprout Pharms products?

Barriers typically include:

• process patents that constrain manufacturing approaches,
• CMC complexity that raises the cost of approval and post-approval changes,
• and formulation or stability requirements that increase the development burden.

In practical terms, the most enforceable barriers are those that tie directly to approved specs and label-critical performance characteristics.

Where can Sprout Pharms expand for better competitive defensibility?

Competitive defensibility improves when expansion targets:

• products with clear patent-listed protection around dosage form or stability,
• formulations that increase design-around cost,
• and lifecycle assets that are less vulnerable to label-only carve-outs.

The highest return on investment comes from pairing pipeline selection with a litigation strategy that is designed around claim-type-specific vulnerabilities.

Key product and competitor comparison: how market position is likely to shift

A high-signal comparison framework for Sprout versus competitors uses launch timing rather than marketing claims.

Comparison dimensions that usually drive outcomes

Last updated: June 17, 2026

• Expected first competitive entry date vs expected second-wave entry
• Exclusivity corridor length (patent and regulatory combined)
• Settlement probability and typical entry concessions
• Net price trajectories after 1st and 2nd competitor entries
• Supply ramp capacity and shortage history

Key Takeaways

• Sprout Pharms’ competitive position is strongest where it can convert exclusivity and settlement timing into dependable, calendar-driven launches.
• Competitive pressure rises in clustered patent expiry periods, where multiple generic challengers can bundle entry and trigger net price compression.
• Patent estate quality matters more than patent count, with formulation and method-of-use claims providing the most durable entry constraints.
• The largest forward risk is recurring Paragraph IV and design-around pressure across multiple SKUs rather than a single existential patent loss.
• Strategic upside is tied to product selection that pairs enforceable claim types with execution-ready manufacturing and regulatory packages.

FAQs

1. How do 180-day exclusivity periods affect Sprout Pharms’ competitive timelines?
2. What claim types (formulation vs method-of-use) most often determine whether generics can launch against Sprout Pharms products?
3. How do settlement “date-certain” terms typically change Sprout Pharms’ revenue protection window?
4. What Orange Book patent expirations drive the highest risk of near-term price erosion for Sprout Pharms?
5. How does launch supply reliability influence payer and wholesaler switching after generic entry?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration. Hatch-Waxman Amendments and ANDA Exclusivity (FDA guidance and related materials).